Phase IIa Study of BRY812 Monotherapy in Advanced Gynecological Malignancies

NCT07311538 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Gynecological Malignancies

Interventions

DRUG: BRY812 for injection

Sponsor

BioRay Pharmaceutical Co., Ltd.